Financials Sirio Pharma Co., Ltd.

Equities

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
41.69 ^CNY	-0.88%		+6.82%	+20.28%

04-21	Sirio Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-19	Tranche Update on Sirio Pharma Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023.	CI

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	11,035	7,513	6,637	6,293	7,516	-	-
Enterprise Value (EV) ¹	11,035	7,513	6,637	6,293	7,516	7,516	7,516
P/E ratio	28.6 x	34.2 x	31.5 x	22.2 x	19 x	15.5 x	12.8 x
Yield	-	0.96%	0.95%	3.17%	3.77%	4.39%	-
Capitalization / Revenue	-	3.17 x	2.65 x	1.76 x	1.72 x	1.5 x	1.31 x
EV / Revenue	-	3.17 x	2.65 x	1.76 x	1.72 x	1.5 x	1.31 x
EV / EBITDA	-	-	16.7 x	10.7 x	9.72 x	8.2 x	8.12 x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Price to Book	-	3.21 x	2.65 x	2.88 x	2.91 x	2.61 x	2.31 x
Nbr of stocks (in thousands)	180,000	180,170	180,497	181,562	180,277	-	-
Reference price ²	61.31	41.70	36.77	34.66	41.69	41.69	41.69
Announcement Date	27/04/21	11/04/22	20/04/23	21/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	2,369	2,507	3,582	4,359	5,026	5,741
EBITDA ¹	-	-	396.6	585.8	773.5	916.5	926
EBIT ¹	-	289.8	265.1	282	443	580.7	717.5
Operating Margin	-	12.23%	10.57%	7.87%	10.16%	11.55%	12.5%
Earnings before Tax (EBT) ¹	-	280.9	251.5	273.3	440.7	578	712.5
Net income ¹	257.4	231.8	212.3	281	399	488.3	591.5
Net margin	-	9.79%	8.47%	7.85%	9.15%	9.72%	10.3%
EPS ²	2.140	1.220	1.168	1.558	2.197	2.690	3.255
Free Cash Flow	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	-	0.4000	0.3500	1.100	1.570	1.830	-
Announcement Date	27/04/21	11/04/22	20/04/23	21/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	9.77%	8.12%	12.1%	15.6%	17.1%	18%
ROA (Net income/ Total Assets)	-	-	5.3%	-	7%	7.75%	8.6%
Assets ¹	-	-	4,003	-	5,700	6,301	6,878
Book Value Per Share ²	-	13.00	13.90	12.10	14.40	15.90	18.10
Cash Flow per Share ²	-	1.890	2.460	2.130	3.260	4.160	3.370
Capex ¹	-	524	294	449	310	310	310
Capex / Sales	-	22.13%	11.71%	12.53%	7.11%	6.17%	5.4%
Announcement Date	27/04/21	11/04/22	20/04/23	21/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.69 CNY

Average target price

41.67 CNY

Spread / Average Target

-0.06%

	1st Jan change	Capi.
SIRIO PHARMA CO., LTD.	+20.28%	1.04B
ZHEJIANG NHU COMPANY LTD.	+16.80%	8.43B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+15.02%	6.82B
THE SIMPLY GOOD FOODS COMPANY	-4.77%	3.77B
BYHEALTH CO., LTD	-6.75%	3.74B
XIAMEN KINGDOMWAY GROUP COMPANY	+4.41%	1.44B
HERBALIFE LTD.	-30.34%	1.06B
USANA HEALTH SCIENCES, INC.	-12.85%	890M
JAMIESON WELLNESS INC.	-15.63%	812M
GRAPE KING BIO LTD	+2.88%	732M